Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 3/20 | 0.64 |
| ▸ | MMP2 | P08253 | 3/20 | 0.63 |
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5898017 | 0.97 | ADAM17 (0.65) | ADAM17MMP2MMP9 | |
| SCHEMBL5897871 | 0.97 | ADAM17 (0.68) | ADAM17MMP2MMP9 | |
| SCHEMBL5898195 | 0.94 | ADAM17 (0.69) | ADAM17MMP2MMP9 | |
| Trifluoroacetic Acid SCHEMBL5898367 | 0.94 | ADAM17 (0.73) | ADAM17MMP2MMP9 | |
| Trifluoroacetic Acid SCHEMBL5897958 | 0.94 | ADAM17 (0.73) | ADAM17MMP2MMP9 | |
| SCHEMBL5898176 | 0.92 | MMP2 (0.70) | ADAM17MMP2MMP9 | |
| SCHEMBL5898153 | 0.92 | MMP2 (0.70) | ADAM17MMP2MMP9 | |
| SCHEMBL5898162 | 0.92 | MMP2 (0.70) | ADAM17MMP2MMP9 | |
| Trifluoroacetic Acid SCHEMBL5898370 | 0.91 | MMP2 (0.66) | MMP2 | |
| Trifluoroacetic Acid SCHEMBL5898236 | 0.91 | MMP2 (0.66) | MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743807-B2 | TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, TUMOR METASTASIS OR INVASION, PERIODONTAL DISEASE AND BONE DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | ADAM17 18/4885MMP2 8/4885MMP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.